Med：国产减肥药玛仕度肽安全有效减轻中国肥胖患者体重，并改善心血管代谢健康

Core Viewpoint - Mazdutide, developed by Innovent Biologics, is a dual receptor agonist targeting GLP-1 and GCG, showing potential for weight loss and improvement in liver fat metabolism in obese individuals without diabetes [2][3]. Group 1: Clinical Trial Results - A Phase 2 randomized controlled trial demonstrated that Mazdutide 9 mg led to a weight reduction of 15.4% compared to the placebo group at 24 weeks, with further weight loss observed at 48 weeks [3][5]. - The trial involved 80 participants with a mean BMI of 34.3 and mean weight of 96.9 kg, showing significant efficacy in weight management [4][5]. - At 24 weeks, 81.7% of patients on Mazdutide experienced a weight loss of 5% or more, with 31.7% losing 15% or more, while the placebo group showed no significant weight loss [5][8]. Group 2: Safety and Side Effects - The treatment was associated with improvements in cardiovascular metabolic risk factors, with common side effects including nausea (50% in the treatment group), diarrhea (38.3%), and vomiting (36.7%), mostly mild to moderate [7][8]. - The safety profile of Mazdutide 9 mg was deemed acceptable for the target population of Chinese adults with obesity and no diabetes [8].